Tectonic Therapeutic, Inc.
NASDAQ:TECXBiotechnology
-$0.29 today
- Market cap
- $411.32M
- Beta
- 1.22
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.45
Volume 0.17M
Average 0.20M
TECX Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Tectonic Therapeutic, Inc.NASDAQ: TECX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $304K fell 15.6% year over year, behind the +3.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 56.1% from the prior quarter. Over 3 fiscal years it compounded at +11.0% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -15.6% toward the trailing-twelve-month pace of +3.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.38M USD
- Year-over-year change
- -16.4%
- 4-year CAGR
- +39.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.38M | -16.4% |
| FY2024 | 2024-12-31 | 1.65M | +11.3% |
| FY2023 | 2023-12-31 | 1.48M | +46.9% |
| FY2022 | 2022-12-31 | 1.01M | +176.4% |
| FY2021 | 2021-12-31 | 364K | — |
Depreciation & Amortization vs competitors
How TECX compares with its peers on the latest reported figures
- TECX's LTM Mar 2026 depreciation & amortization of $1.68M is the 3rd highest of the 4 companies compared; the peer median is $1.92M.
- Its year-over-year change of +3.1% is the 2nd highest of 4, against a peer median of -14.1%.
- Over three fiscal years its annual growth of +11.0% compares with a peer median of +141.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
GENBGenerate Biomedicines, Inc. | FY2025 | $13.18M | -14.1% | — | 41.3% |
| LTM Jun 2026 | $1.92M | +74.2% | +141.5% | — | |
TECXTectonic Therapeutic, Inc. | LTM Mar 2026 | $1.68M | +3.1% | +11.0% | — |
SEPNSepterna, Inc. | LTM Sep 2026 | $1.25M | -21.5% | — | 1.3% |
| Peer median (excluding TECX) | $1.92M | -14.1% | +141.5% | 21.3% | |
Competitors are the stored peer set for TECX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.98M | 25.65M | 36.97M | 41.36M | 63.49M |
| Selling, General & Admin | 4.63M | 7.18M | 7.68M | 16.65M | 20.55M |
| Operating Expenses | 15.61M | 32.83M | 44.65M | 58.02M | 84.04M |
| Depreciation & Amortization | 364K | 1.01M | 1.48M | 1.65M | 1.38M |
| EBITDA | (8.12M) | (31.03M) | (41.19M) | (56.23M) | (71.48M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (15.61M) | (32.83M) | (44.65M) | (58.02M) | (84.04M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 149K | 581K | 4.26M | 11.3M |
| Interest Expense | 224K | 144K | 152K | 107K | 63K |
| Other Income / Expenses | 6.68M | 650K | 1.83M | 33K | 11.12M |
| Income Before Tax | (8.93M) | (32.18M) | (42.82M) | (57.98M) | (72.92M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.23M |
| Net Income | (8.93M) | (32.18M) | (42.82M) | (57.98M) | (74.15M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (33.36) | (29.05) | (11.59) | (3.93) | (4.05) |
| EPS (Diluted) | (33.36) | (29.05) | (11.53) | (3.93) | (4.05) |
| Weighted Avg Shares | 3.57M | 3.64M | 3.69M | 14.77M | 18.32M |
| Weighted Avg Shares (Diluted) | 3.57M | 3.64M | 3.71M | 14.77M | 18.32M |
Tectonic Therapeutic, Inc.
NASDAQ:TECX
Intrinsic Alpha fair value
Locked
Current Price
$21.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.